The Week in Tech: AI Model Wars, Affordable Solid-State EVs, and CRISPR’s New Chapter

The AI Model Rush Has No Signs of Slowing

Between early April and mid-May 2026, major AI labs shipped roughly nineteen notable model releases in a single thirty-day window. OpenAI, Anthropic, Google, Meta, DeepSeek, Alibaba, and others all released updates to frontier or near-frontier systems simultaneously. For teams evaluating production options, this is both an embarrassment of riches and a genuine cost-risk minefield.

GPT-5.5 Raises the Ceiling — and the Bill

OpenAI released GPT-5.5 on April 23, 2026. It currently leads the Artificial Analysis Intelligence Index at a score of sixty, up meaningfully from the GPT-5.4 generation. On SWE-bench Verified, it reaches 88.7%, compared with roughly 74% for its predecessor. OpenAI also touts a net intelligence gain of about 20% once token efficiency is factored in.

The catch is pricing. Input tokens cost $5 per million and output tokens cost $30 per million, effectively doubling the output price of the GPT-5 line. There is also a Pro tier at $30/$180 for parallel-reasoning workloads, plus a lighter Instant variant that arrived in early May. For a solopreneur or small team, GPT-5.5 is the right tool for high-stakes coding, computer-use agents, or dense analytical work, but using it as a general default across every feature will burn budget fast.

Claude Opus 4.7: Transparent About Its Limits

Anthropic shipped Claude Opus 4.7 on April 16, 2026, and was unusually candid at launch: the company conceded that Opus 4.7 trails an unreleased internal model codenamed Mythos, which it held back as the lower-risk option to ship publicly. The verified gains over Opus 4.6 are solid rather than spectacular — SWE-bench Verified moves from 80.8% to 87.6%, Terminal-Bench 2.0 reaches 69.4%, and GPQA Diamond scores 94.2%. Finance Agent sits at 64.4%, and the model scores 57 on the Artificial Analysis Intelligence Index.

One design change worth pricing in: Opus 4.7 ships with an updated tokenizer that can map the same input to roughly 1.0× to 1.35× more tokens than before. Sticker pricing stayed at $5/$25 per million tokens, but your real per-request cost can rise even though the listed rate did not. It is also the first Claude with high-resolution image input, supporting up to 2,576 pixels on the long edge, which matters if you are feeding it screenshots, documents, or diagrams.

Gemini 3.5 Flash Wins on Price

Google released Gemini 3.5 Flash in mid-May at $1.50/$9 per million tokens in/out, easily the cheapest of the three flagship models discussed here. Where it fits is high-volume, latency-sensitive work where raw capability above a certain floor is enough. It is not the model you reach for when correctness on a hard, well-defined task matters more than cost, but for consumer-facing assistants and batch operations it changes the economics of running AI at scale.

For anyone building production AI features in 2026, the practical takeaway is flattening the old assumption that one model must handle every load. Use GPT-5.5 sparingly for complex coding and agentic tasks, Opus 4.7 for long-horizon work and high-resolution document understanding, and Gemini 3.5 Flash for volume workloads where the per-token bill matters more than the leaderboard rank.

Enterprise Agent Platforms Are Getting Real

Beyond raw model benchmarks, the infrastructure layer for AI agents is maturing rapidly. Google launched the Gemini Enterprise Agent Platform in April 2026, giving teams a production-oriented environment for deploying coordinated agents with shared business context. Microsoft released Agent Framework Version 1.0, targeting .NET developers who want to build, test, and deploy multi-agent systems without hand-rolling orchestration from scratch. OpenAI, meanwhile, is pushing its Frontier tier, which pairs premium model access with shared business context and Forward Deployed Engineers for enterprise customers.

For teams deciding where to invest engineering time, the question is less about which platform is best and more about which one aligns with existing skill sets and cloud contracts. Google and Microsoft are both leaning hard into their established ecosystems. If you are already operating in GCP or Azure, the path of least resistance is becoming clear. Open-source alternatives and smaller agent frameworks remain viable, but they increasingly require more glue code to match the out-of-the-box reliability of the hyperscaler stacks.

EVs: Solid-State Batteries Hit the Mass Market

On the automotive front, Chinese automaker SAIC launched the MG 4X, an electric SUV powered by a semi-solid-state battery starting at 99,800 yuan — roughly $14,700 — in China, or as low as $13,700 with limited-time incentives. That matters because solid-state batteries have long been treated as a future technology, perpetually five to ten years away from affordability. With the MG 4X, that future just arrived at sub-$15,000 pricing.

The semi-solid-state pack from SAIC Qingtao holds 53.9 kWh and delivers up to 510 km under China’s CLTC cycle. An optional 64.2 kWh CATL LFP pack extends that to 610 km. SAIC says the electrolyte content is reduced to just 5%, which the company claims cuts combustion risk and improves cycle life. The battery reportedly survived two needle-penetration tests with no smoke, fire, or explosion after two hours, exceeding industry standards by 20%, according to SAIC.

On the higher end, Mercedes-AMG unveiled the all-electric second-generation GT 4-Door Coupé, debuting with up to 1,169 horsepower and a claimed 435 miles of WLTP range. The headline tech is British-developed axial flux motors from Yasa, the Oxfordshire company Mercedes-Benz acquired in 2021. The rear motors are roughly eight centimeters wide; the front motor is around nine centimeters. Despite the tiny packaging, the setup produces more power than many hypercars, with 2,000 Nm of torque in top GT 63 trim.

Mercedes also built what it calls the AMGFORCE S+ mode, mixing more than 1,600 individual sound files in real time to mimic the character of a V8 engine, complete with simulated gearshifts. The battery is an 800-volt system with directly cooled cylindrical cells influenced by Formula 1 technology. Charging speed is claimed at up to 600 kW, adding roughly 286 miles of range in ten minutes and reaching 10% to 80% in eleven minutes.

These two releases bookend the current state of EVs nicely: mass-market solid-state cells storming through the price floor on one end, and high-performance electrification reaching formerly impossible power figures on the other.

Biotech: CRISPR Moves From Hype to Clinical Reality

In biotech, Intellia Therapeutics announced that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran — known as lonvo-z — hit its primary endpoint in a phase 3 trial for hereditary angioedema. The data showed an 87% reduction in HAE attacks, with more than 60% of patients attack-free and therapy-free during the evaluation period. Intellia is now racing to file for FDA approval, following what it described as a compelling picture from the late-stage data.

Separately, CRISPR Therapeutics and Vertex Pharmaceuticals presented 36-month follow-up data from their Casgevy therapy for sickle-cell disease. The results continued to confirm durable functional cures, reinforcing Casgevy’s position as one of the most clinically validated CRISPR medicines on the market. Cleveland Clinic also released results showing near-universal functional cure rates with a gene-editing therapy for severe sickle-cell disease, adding to a growing body of evidence that one-time curative treatments may be realistic outside ultra-rare diseases.

Why This Matters for the Broader Tech Conversation

These biotech advances are important context for anyone watching AI-driven drug discovery. Gene editing is becoming a proven engineering discipline: exact cuts, predictable outcomes, regulatory pathways. That creates a much more attractive substrate for AI-assisted molecular design, because the underlying biology is finally precise enough to model reliably. Tools that predict off-target effects, optimize guide RNA, or simulate repair outcomes become genuinely valuable when the foundational technology works at scale.

The Quarter-Long Snapshot

If you are running a product or engineering organization, the connective tissue across these stories is precision. Frontier AI models are racing toward more exact reasoning, more controlled costs, and more predictable agentic behavior. Solid-state batteries are finally making the jump from lab demos to showroom pricing. And CRISPR therapies are proving that exact biological edits can work in real patients, over long timelines, with regulatory backing.

Precision is the through-line. In each case, a technology that was promising in principle spent years struggling with inconsistency, cost, or safety objections. In 2026, all three domains are crossing thresholds where those gaps are closing fast enough to matter for builders, buyers, and patients alike.

Sources: Artificial Analysis Intelligence Index; OpenAI system card for GPT-5.5; Anthropic model notes for Claude Opus 4.7; Electrek coverage of SAIC MG 4X launch; Mercedes-AMG press materials on second-generation GT 4-Door Coupé; Intellia Therapeutics phase 3 announcement via Fierce Biotech; CRISPR Therapeutics/Vertex 36-month Casgevy data follow-up.